Search Results for "Immunizations"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Immunizations. Results 291 to 300 of 421 total matches.

Treatment of Common Respiratory Tract Infections

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
common bacterial pathogens. Since the introduction of routine pneumococcal vaccination ...
Most respiratory tract infections are caused by viruses. Bacterial respiratory tract infections are usually treated empirically with antibiotic therapy that targets the most probable causative pathogens. Recommended antibiotic regimens for outpatient treatment of some common respiratory tract infections are listed in Table 1 for adults and Table 2 for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62   doi:10.58347/tml.2023.1674a |  Show IntroductionHide Introduction

Rocuronium - A New Neuromuscular Blocker

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 1994  (Issue 928)
bromide Zemuron Vecuronium Correction typhoid vaccine correction Tracrium Succinylcholine ...
Rocuronium bromide (Zemuron - Organon), a new short-onset, intermediate-acting, nondepolarizing neuromuscular blocking drug, is now available in the USA for intravenous use. It is being promoted particularly for use in rapid endotracheal intubation.
Med Lett Drugs Ther. 1994 Aug 5;36(928):71-2 |  Show IntroductionHide Introduction

Alpha-L-Iduronidase (Laronidase; Aldurazyme)

   
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003  (Issue 1168)
developed antibodies to the enzyme early in treatment developed immune tolerance (no antibody response) over ...
Recombinant human α-L-iduronidase (laronidase; Aldurazyme BioMarin/Genzyme), an orphan drug, has been approved by the FDA for enzyme replacement therapy in mucopolysaccharidosis (MPS) type I, a lysosomal storage disorder caused by deficiency of the enzyme. This review describes the disease, treatment, adverse effects and cost.
Med Lett Drugs Ther. 2003 Oct 27;45(1168):88 |  Show IntroductionHide Introduction

Capsaicin Patch (Qutenza) for Postherpetic Neuralgia

   
The Medical Letter on Drugs and Therapeutics • May 30, 2011  (Issue 1365)
of the patch. o 1. Herpes zoster vaccine (Zostavax). Med Lett Drugs Ther 2006; 48: 73. The Medical Letter ...
The FDA has approved a topical 8% patch formulation of capsaicin (Qutenza – NeurogesX), available only by prescription, for local treatment of postherpetic neuralgia. Postherpetic neuralgia occurs after herpes zoster in about one third of patients ≥60 years old and can persist for months or even years.
Med Lett Drugs Ther. 2011 May 30;53(1365):42-3 |  Show IntroductionHide Introduction

Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2011  (Issue 1366)
— In the higher doses used to suppress cardiac arrhythmias, quinidine can cause immune-mediated thrombocytopenia ...
The FDA has approved Nuedexta (Avanir), a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for oral treatment of pseudobulbar affect. The combination is the first treatment approved by the FDA for this indication. Studies to support the effectiveness of Nuedexta were performed in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS); the drug has not been shown to be safe or effective in other types of emotional lability.
Med Lett Drugs Ther. 2011 Jun 13;53(1366):46-7 |  Show IntroductionHide Introduction

Tocilizumab (Actemra) for Giant Cell Arteritis

   
The Medical Letter on Drugs and Therapeutics • Sep 25, 2017  (Issue 1530)
tuberculosis is required before starting the drug. Live vaccines should not be administered during ...
The FDA has approved the interleukin-6 (IL-6) receptor antagonist tocilizumab (Actemra – Genentech) for subcutaneous (SC) treatment of giant cell arteritis in adults. It is the first drug to be approved in the US for this indication. Tocilizumab is also approved for treatment of rheumatoid arthritis, polyarticular or systemic juvenile idiopathic arthritis, and cytokine release syndrome.
Med Lett Drugs Ther. 2017 Sep 25;59(1530):161-2 |  Show IntroductionHide Introduction

Rilonacept (Arcalyst) for Recurrent Pericarditis

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021  (Issue 1632)
may interfere with immune responses to infection. Hypersensitivity reactions have occurred rarely. Letter ...
Rilonacept (Arcalyst – Kiniksa), an interleukin-1 (IL-1) antagonist that has been available for years for treatment of cryopyrin-associated periodic syndromes, has now been approved by the FDA for treatment of recurrent pericarditis and prevention of further recurrences in patients ≥12 years old. It is the first drug to be approved in the US for this indication. Anakinra (Kineret), an IL-1 receptor antagonist FDA-approved for treatment of rheumatoid arthritis, has been used off-label for years for treatment of recurrent pericarditis.
Med Lett Drugs Ther. 2021 Sep 6;63(1632):143-4 |  Show IntroductionHide Introduction

Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
the risks of cytokine release syndrome (CRS) and life-threatening or fatal immune effector cell-associated ...
Epcoritamab-bysp (Epkinly – Genmab), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for subcutaneous treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥2 lines of systemic therapy. Epcoritamab is the second T-cell-engaging bispecific antibody to become available in the US for treatment of non-Hodgkin's lymphoma; mosunetuzumab-axgb (Lunsumio) was recently approved for relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-4   doi:10.58347/tml.2023.1678d |  Show IntroductionHide Introduction

Talquetamab (Talvey) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
warning about the risks of cytokine release syndrome (CRS) and neurologic toxicity, including immune ...
Talquetamab-tgvs (Talvey – Janssen), a bispecific GPRC5D-directed T-cell engager, has been granted accelerated approval by the FDA for treatment of relapsed or refractory multiple myeloma in adults who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Accelerated approval was based on the response rate and durability of response. Talquetamab is the first bispecific GPRC5D-directed T-cell engager to be approved in the US
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e149-50   doi:10.58347/tml.2023.1684e |  Show IntroductionHide Introduction

Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023  (Issue 1686)
of efavirenz and valoctocogene roxaparvovec is not recommended. Live vaccines should not be administered ...
Valoctocogene roxaparvovec-rvox (Roctavian – Biomarin), an adeno-associated virus (AAV) vector-based gene therapy, has been approved by the FDA for one-time treatment of severe hemophilia A in adults without pre-existing antibodies to AAV serotype 5. It is the first gene therapy to be approved in the US for treatment of hemophilia A.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):157-8   doi:10.58347/tml.2023.1686c |  Show IntroductionHide Introduction